Accession Number : ADA185457

Title :   Chemotherapy and Biochemistry of Leishmania.

Descriptive Note : Annual rept. 1 Jan-31 Dec 84,

Corporate Author : MASSACHUSETTS UNIV AMHERST DEPT OF MICROBIOLOGY

Personal Author(s) : Nolan, Linda L

PDF Url : ADA185457

Report Date : Dec 1984

Pagination or Media Count : 51

Abstract : A comparison of the enzymes of pathogenic protozoa to those of man is of fundamental importance to the search for much needed chemotherapeutic agents. The enzymes involved in purine salvage are of particular interest because most pathogenic protozoa lack the ability to synthesize purines de novo and consequently are obligate salvagers of preformed purines. A workshop on antileishmanial drug development was set up at WRAIR for the purpose of establishing a major intermural, multidisciplinary drug development research effort. This antileishmananial research program is being directed through the Division of Experimental Therapeutics, and includes three laboratories at WRAIR and three U.S. university laboratories. The role of this laboratory in the program is to test compounds in vivo using different Leishmania spp. and to determine the molecular mode of action of promising compounds. Compounds provided by WRAIR were tested singly, and for synergy, in combination. The most promising compounds to date sent by WRAIR appear to be the following: BK63005 3-B-D-Ribofurano-sylpyrazolo-4,3-D pyrimidin-7-thione; BK74731 oxoformycin B; BK63863 Thiopurinol riboside; BK71338 oxoformysin A; BK86124 Allopurinol riboside; and 9 Deazainosine.

Descriptors :   *LEISHMANIA, *ANTIPARASITIC DRUGS, *BIOCHEMISTRY, CHEMOTHERAPEUTIC AGENTS, ENZYMES, PURINES, IN VIVO ANALYSIS, MOLECULAR PROPERTIES, BIOASSAY, METABOLISM

Subject Categories : Microbiology
      Pharmacology
      Biochemistry

Distribution Statement : APPROVED FOR PUBLIC RELEASE